ACM
CYT

ACT Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

ACT Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$29K Hold
15,000
– – 0.04% 62
2022
Q2 		$45K Hold
15,000
– – 0.06% 65
2022
Q1 		$57K Hold
15,000
– – 0.06% 75
2021
Q4 		$171K Hold
15,000
– – 0.12% 70
2021
Q3 		$263K Buy
15,000
+14,910
+16,567% +$279K 0.14% 76
2021
Q2 		$2K Buy
+90
New +$1.69K ﹤0.01% 116

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACT Capital Management's CYT Position: Q3 2022 in Review

ACT Capital Management held its Cyteir Therapeutics, Inc. Common Stock (CYT) position steady in Q3 2022 at 15,000 shares worth $29K. The position accounts for 0.04% of the portfolio, ranked #62.

ACT Capital Management first reported a position in CYT in Q2 2021 and has held it in 6 quarters since. The position peaked at $263K in Q3 2021. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • ACT Capital Management held 15,000 shares of Cyteir Therapeutics, Inc. Common Stock worth $29K as of Q3 2022.
  • ACT Capital Management left its Cyteir Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
  • Cyteir Therapeutics, Inc. Common Stock made up 0.04% of ACT Capital Management's portfolio in Q3 2022, its #62 holding.
  • ACT Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $263K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.